{"altmetric_id":4631153,"counts":{"readers":{"mendeley":81,"citeulike":0,"connotea":0},"total":{"posts_count":2},"twitter":{"unique_users_count":2,"unique_users":["tiger_shark5039","WilliamGerber1"],"posts_count":2}},"citation":{"altmetric_jid":"4f6fa8f03cf058f61000c819","authors":["Seth A. Wander","Mark J. Levis","Amir T. Fathi"],"doi":"10.1177\/2040620714532123","first_seen_on":"2015-10-15T21:35:20+00:00","issns":["2040-6207"],"issue":"3","journal":"Therapeutic Advances in Hematology","last_mentioned_on":1455903774,"links":["http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4031904\/"],"pmcid":"PMC4031904","pmid":"24883179","pubdate":"2014-06-01T00:00:00+00:00","publisher":"SAGE Publications","startpage":"65","title":"The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond","type":"article","volume":"5","mendeley_url":"http:\/\/www.mendeley.com\/research\/evolving-role-flt3-inhibitors-acute-myeloid-leukemia-quizartinib-beyond"},"altmetric_score":{"score":2,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":2},"context_for_score":{"all":{"total_number_of_other_articles":7214390,"mean":6.3538386288811,"rank":2920776,"this_scored_higher_than_pct":58,"this_scored_higher_than":4188731,"rank_type":"exact","sample_size":7214390,"percentile":58},"similar_age_3m":{"total_number_of_other_articles":238432,"mean":9.325588887351,"rank":87360,"this_scored_higher_than_pct":61,"this_scored_higher_than":146542,"rank_type":"exact","sample_size":238432,"percentile":61},"this_journal":{"total_number_of_other_articles":55,"mean":6.2472962962963,"rank":14,"this_scored_higher_than_pct":74,"this_scored_higher_than":41,"rank_type":"exact","sample_size":55,"percentile":74},"similar_age_this_journal_3m":{"total_number_of_other_articles":3,"mean":0.5,"rank":1,"this_scored_higher_than_pct":66,"this_scored_higher_than":2,"rank_type":"exact","sample_size":3,"percentile":66}}},"demographics":{"poster_types":{"member_of_the_public":1,"practitioner":1},"users":{"twitter":{"cohorts":{"Practitioners (doctors, other healthcare professionals)":1,"Members of the public":1}},"mendeley":{"by_status":{"Researcher":15,"Student  > Doctoral Student":6,"Student  > Ph. D. Student":27,"Student  > Postgraduate":3,"Student  > Master":12,"Other":8,"Student  > Bachelor":8,"Professor":2},"by_discipline":{"Medicine and Dentistry":29,"Chemistry":2,"Immunology and Microbiology":1,"Agricultural and Biological Sciences":33,"Nursing and Health Professions":1,"Biochemistry, Genetics and Molecular Biology":12,"Pharmacology, Toxicology and Pharmaceutical Science":3}}},"geo":{"twitter":{"US":1}}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/tiger_shark5039\/statuses\/654772493069127680","license":"gnip","citation_ids":[4631153],"posted_on":"2015-10-15T21:35:02+00:00","author":{"name":"tiger","image":"https:\/\/pbs.twimg.com\/profile_images\/660155702636220417\/VSm_589w_normal.jpg","description":"Private investor-trader, COO Private Trust Fund \nMedical Technologist, sarcasm, humor all part of life, enjoy All opinions are my own and not investment advice","id_on_source":"tiger_shark5039","tweeter_id":"147981511","geo":{"lt":"34.9550817","ln":"-97.2684063","country":"US"},"followers":1398},"tweet_id":"654772493069127680"},{"url":"http:\/\/twitter.com\/WilliamGerber1\/statuses\/700737333914574848","license":"gnip","citation_ids":[4631153],"posted_on":"2016-02-19T17:42:54+00:00","author":{"name":"William Gerber","image":"https:\/\/pbs.twimg.com\/profile_images\/702966431001022464\/ZS-vIwhm_normal.jpg","description":"Interested in Biotech w\/ focus on new drugs. Long only. Want to hear all sides of argument, even if I own the stock. Relentless stock cheerleading = red flag.","id_on_source":"WilliamGerber1","tweeter_id":"1055551057","geo":{"lt":null,"ln":null},"followers":1716},"tweet_id":"700737333914574848"}]}}